VTAK Stock Pops As Flyte Bets Big On AI Aviation

Catheter Precision Inc. surges as strong clinical news and investor optimism drive momentum; stocks have been trading up by 63.08 percent.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading VTAK

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Through its Flyte unit, Catheter Precision took a 7.5% stake in Volato Group, becoming its largest shareholder to drive collaboration in private aviation.
The company led a $2.2M strategic PIPE into Volato to fund AI-enabled private aviation and regional air mobility projects.
Flyte partnered with GSE Worldwide and PGA TOUR golfer Emiliano Grillo, debuting at the 2026 U.S. Open to market its Cirrus Vision Jet short-haul service.
VTAK shares jumped nearly 3% after news of the Volato financing and 7.5% stake.
Catheter Precision (VTAK) remains closely tied to Creatd, which still holds equity, preferred stock, and note receivables related to the Flyte acquisition.

Live Update At 10:05:21 EDT: On Wednesday, June 24, 2026 Catheter Precision Inc. stock [NYSE American: VTAK] is trending up by 63.08%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

VTAK is trading like a classic high-volatility small cap. The daily chart shows Catheter Precision grinding between roughly $0.82 and $1.10 for most of early 2026, then exploding to a $1.79 high on 2026/06/24 before closing near $1.505. That is a big range for a sub-$2 stock and tells traders momentum is back in play.

Intraday, VTAK opened at $1.10, spiked into the $1.80–$2.00 zone in early regular trading, then faded but held above $1.50. Volume-backed spikes followed by higher lows are the pattern traders want to see when a story is heating up.

Under the hood, Catheter Precision is still a heavy cash burner. Quarterly revenue is just $432,000, with about $819,000 over the last year, and EBITDA sits deep in the red at around -$1.35M. Operating cash flow for the quarter was roughly -$2.80M, partially plugged by $4.47M in financing cash inflows. The balance sheet shows only $441,000 in cash against current liabilities of $19.7M and a current ratio near 0.1 — tight.

More Breaking News

For traders, that combo of low float, negative earnings, and aggressive financing around Flyte and Volato sets up a classic catalyst-driven momentum name rather than a balance-sheet comfort play.

Why Traders Are Watching VTAK’s Flyte And Volato Moves

The real story in VTAK right now is not legacy medtech. It is aviation. Through its Flyte subsidiary, Catheter Precision stepped in as lead on a broader Volato Group financing, grabbing about 2.9M Volato shares for a 7.5% stake and the title of largest shareholder. The market noticed; Catheter Precision’s stock rallied nearly 3% on that news alone.

For active traders, that kind of strategic equity move is key. VTAK is not just buying random stock. It is using Flyte’s capital to lock in a seat at the table in private aviation, especially regional air mobility. The $2.2M PIPE into Volato is earmarked for AI-enabled private aviation and infrastructure. That tells traders what management wants the story to be: an AI plus aviation growth play layered on top of a struggling core business.

Flyte is not staying in stealth mode, either. Catheter Precision pushed its aviation brand into the spotlight by teaming up with GSE Worldwide and PGA TOUR pro Emiliano Grillo, debuting at the 2026 U.S. Open. The plan is simple and smart for a small brand: put Flyte’s Cirrus Vision Jet short-haul service in front of high-net-worth athletes and the broader sports ecosystem. If even a slice of that audience adopts, the narrative around VTAK can accelerate.

There is also the Creatd angle. Catheter Precision bought Flyte from Creatd and still stands as a major client and strategic partner. Creatd retains meaningful equity, preferred stock, and note receivables tied to the deal. For traders, that web of obligations shows Flyte is considered valuable, but it also adds complexity to VTAK’s capital stack that can matter if more funding is needed down the road.

Conclusion

Catheter Precision has turned VTAK into a hybrid story: early-stage medtech plus a high-concept bet on AI-enabled regional air mobility. The stock’s surge from sub-$1 to intraday highs near $2.00 on 2026/06/24 lines up with this news cycle — Flyte leading Volato’s financing, taking a 7.5% stake, and rolling out marketing with a PGA TOUR golfer at a major championship.

From a pure fundamentals standpoint, VTAK’s numbers are rough. Margins are deeply negative, free cash flow is around -$2.80M for the quarter, and the current ratio is extremely low. That is why traders need to treat Catheter Precision as a speculative, catalyst-driven ticker, not a steady compounder. Dilution risk and financing needs remain front and center.

But speculative does not mean untradeable. It means you trade the chart and the catalysts, not a long-term story you fell in love with. VTAK’s tight float, sharp intraday ranges, and AI-aviation headlines create the kind of volatility active traders seek — both long and short, depending on the setup. This is exactly where process and discipline matter: as Tim Bohen, lead trainer with StocksToTrade says, “I focus on what a stock is doing, not what I want it to do. Let the stock prove itself before you make a move.” Applied to VTAK, that means letting price action and liquidity confirm your thesis before committing capital, and reacting to what the ticker actually does intraday instead of forcing a narrative.

As Tim Sykes likes to remind his students, “Patterns repeat, but only for disciplined traders who cut losses quickly and never marry a stock.” VTAK fits that mindset perfectly right now: a volatile story play where preparation, risk management, and strict trading rules matter more than the hype. This analysis is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!